Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R)

Davide Bolignano, Maria Antonietta Medici, Giuseppe Coppolino, Maria Teresa Sciortino, Francesca Marino Merlo, Susanna Campo, Valentina Donato, Assunta Venuti, Alessio Sturiale, Daniela Zaccaria, Antoine Buemi, Antonio Lacquaniti, Michele Buemi

Research output: Contribution to journalArticle

Abstract

Vasopressin (AVP) is a hormone with antidiuretic properties that is also involved in cellular proliferation of breast, pulmonary, and pancreatic neoplasias, attributable to the interaction with specific receptors, among which is the V2-R. Using a culture model of CAKI-2 and A498 cancer cells, our study aimed to verify if renal carcinoma cells also express V2-R and whether receptor activation modulates their proliferation. Immunofluorescence and RT-PCR showed that both CAKI-2 and A498 cells effectively synthesize and express the V2-R. Administration of the vasopressin analogue DDAVP induced an evident growth in both CAKI-2 and A498 cell lines. However, this proliferative effect was completely avoided by the preventive addition of the V2-R antagonist SR121463B (satavaptan). Our study shows for the first time that renal cancer may effectively synthesize and express the V2-R. Furthermore, AVP exerts in vitro a proliferative effect by acting on this receptor, as the selective V2-R blockage is able to completely prevent the cellular growth. A validation of these findings with in vivo models is required to ascertain if the eventual presence of V2-R could influence the aggressiveness of human renal neoplasias. From this point of view, a new, interesting therapeutical application of V2-R antagonists in the treatment of renal cancer could also be proposed, similar to that successfully described in the treatment of autosomal polycystic kidney disease (ADPKD).

Original languageEnglish
Pages (from-to)642-647
Number of pages6
JournalUrologic Oncology: Seminars and Original Investigations
Volume28
Issue number6
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Vasopressin Receptors
Kidney Neoplasms
Vasopressins
Autosomal Dominant Polycystic Kidney
Deamino Arginine Vasopressin
Polycystic Kidney Diseases
Neoplasms
Growth
Renal Cell Carcinoma
Fluorescent Antibody Technique
Breast
Cell Proliferation
Kidney
Cell Line
Polymerase Chain Reaction
Lung
Therapeutics
satavaptan

Keywords

  • Cell proliferation
  • Renal cancer
  • V2-R antagonist
  • V2-receptor
  • Vasopressin

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Bolignano, D., Medici, M. A., Coppolino, G., Sciortino, M. T., Merlo, F. M., Campo, S., ... Buemi, M. (2010). Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R). Urologic Oncology: Seminars and Original Investigations, 28(6), 642-647. https://doi.org/10.1016/j.urolonc.2008.12.014

Aquaretic inhibits renal cancer proliferation : Role of vasopressin receptor-2 (V2-R). / Bolignano, Davide; Medici, Maria Antonietta; Coppolino, Giuseppe; Sciortino, Maria Teresa; Merlo, Francesca Marino; Campo, Susanna; Donato, Valentina; Venuti, Assunta; Sturiale, Alessio; Zaccaria, Daniela; Buemi, Antoine; Lacquaniti, Antonio; Buemi, Michele.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 28, No. 6, 11.2010, p. 642-647.

Research output: Contribution to journalArticle

Bolignano, D, Medici, MA, Coppolino, G, Sciortino, MT, Merlo, FM, Campo, S, Donato, V, Venuti, A, Sturiale, A, Zaccaria, D, Buemi, A, Lacquaniti, A & Buemi, M 2010, 'Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R)', Urologic Oncology: Seminars and Original Investigations, vol. 28, no. 6, pp. 642-647. https://doi.org/10.1016/j.urolonc.2008.12.014
Bolignano, Davide ; Medici, Maria Antonietta ; Coppolino, Giuseppe ; Sciortino, Maria Teresa ; Merlo, Francesca Marino ; Campo, Susanna ; Donato, Valentina ; Venuti, Assunta ; Sturiale, Alessio ; Zaccaria, Daniela ; Buemi, Antoine ; Lacquaniti, Antonio ; Buemi, Michele. / Aquaretic inhibits renal cancer proliferation : Role of vasopressin receptor-2 (V2-R). In: Urologic Oncology: Seminars and Original Investigations. 2010 ; Vol. 28, No. 6. pp. 642-647.
@article{1fcda339f6d34c5fa3d61610aab2beb5,
title = "Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R)",
abstract = "Vasopressin (AVP) is a hormone with antidiuretic properties that is also involved in cellular proliferation of breast, pulmonary, and pancreatic neoplasias, attributable to the interaction with specific receptors, among which is the V2-R. Using a culture model of CAKI-2 and A498 cancer cells, our study aimed to verify if renal carcinoma cells also express V2-R and whether receptor activation modulates their proliferation. Immunofluorescence and RT-PCR showed that both CAKI-2 and A498 cells effectively synthesize and express the V2-R. Administration of the vasopressin analogue DDAVP induced an evident growth in both CAKI-2 and A498 cell lines. However, this proliferative effect was completely avoided by the preventive addition of the V2-R antagonist SR121463B (satavaptan). Our study shows for the first time that renal cancer may effectively synthesize and express the V2-R. Furthermore, AVP exerts in vitro a proliferative effect by acting on this receptor, as the selective V2-R blockage is able to completely prevent the cellular growth. A validation of these findings with in vivo models is required to ascertain if the eventual presence of V2-R could influence the aggressiveness of human renal neoplasias. From this point of view, a new, interesting therapeutical application of V2-R antagonists in the treatment of renal cancer could also be proposed, similar to that successfully described in the treatment of autosomal polycystic kidney disease (ADPKD).",
keywords = "Cell proliferation, Renal cancer, V2-R antagonist, V2-receptor, Vasopressin",
author = "Davide Bolignano and Medici, {Maria Antonietta} and Giuseppe Coppolino and Sciortino, {Maria Teresa} and Merlo, {Francesca Marino} and Susanna Campo and Valentina Donato and Assunta Venuti and Alessio Sturiale and Daniela Zaccaria and Antoine Buemi and Antonio Lacquaniti and Michele Buemi",
year = "2010",
month = "11",
doi = "10.1016/j.urolonc.2008.12.014",
language = "English",
volume = "28",
pages = "642--647",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Aquaretic inhibits renal cancer proliferation

T2 - Role of vasopressin receptor-2 (V2-R)

AU - Bolignano, Davide

AU - Medici, Maria Antonietta

AU - Coppolino, Giuseppe

AU - Sciortino, Maria Teresa

AU - Merlo, Francesca Marino

AU - Campo, Susanna

AU - Donato, Valentina

AU - Venuti, Assunta

AU - Sturiale, Alessio

AU - Zaccaria, Daniela

AU - Buemi, Antoine

AU - Lacquaniti, Antonio

AU - Buemi, Michele

PY - 2010/11

Y1 - 2010/11

N2 - Vasopressin (AVP) is a hormone with antidiuretic properties that is also involved in cellular proliferation of breast, pulmonary, and pancreatic neoplasias, attributable to the interaction with specific receptors, among which is the V2-R. Using a culture model of CAKI-2 and A498 cancer cells, our study aimed to verify if renal carcinoma cells also express V2-R and whether receptor activation modulates their proliferation. Immunofluorescence and RT-PCR showed that both CAKI-2 and A498 cells effectively synthesize and express the V2-R. Administration of the vasopressin analogue DDAVP induced an evident growth in both CAKI-2 and A498 cell lines. However, this proliferative effect was completely avoided by the preventive addition of the V2-R antagonist SR121463B (satavaptan). Our study shows for the first time that renal cancer may effectively synthesize and express the V2-R. Furthermore, AVP exerts in vitro a proliferative effect by acting on this receptor, as the selective V2-R blockage is able to completely prevent the cellular growth. A validation of these findings with in vivo models is required to ascertain if the eventual presence of V2-R could influence the aggressiveness of human renal neoplasias. From this point of view, a new, interesting therapeutical application of V2-R antagonists in the treatment of renal cancer could also be proposed, similar to that successfully described in the treatment of autosomal polycystic kidney disease (ADPKD).

AB - Vasopressin (AVP) is a hormone with antidiuretic properties that is also involved in cellular proliferation of breast, pulmonary, and pancreatic neoplasias, attributable to the interaction with specific receptors, among which is the V2-R. Using a culture model of CAKI-2 and A498 cancer cells, our study aimed to verify if renal carcinoma cells also express V2-R and whether receptor activation modulates their proliferation. Immunofluorescence and RT-PCR showed that both CAKI-2 and A498 cells effectively synthesize and express the V2-R. Administration of the vasopressin analogue DDAVP induced an evident growth in both CAKI-2 and A498 cell lines. However, this proliferative effect was completely avoided by the preventive addition of the V2-R antagonist SR121463B (satavaptan). Our study shows for the first time that renal cancer may effectively synthesize and express the V2-R. Furthermore, AVP exerts in vitro a proliferative effect by acting on this receptor, as the selective V2-R blockage is able to completely prevent the cellular growth. A validation of these findings with in vivo models is required to ascertain if the eventual presence of V2-R could influence the aggressiveness of human renal neoplasias. From this point of view, a new, interesting therapeutical application of V2-R antagonists in the treatment of renal cancer could also be proposed, similar to that successfully described in the treatment of autosomal polycystic kidney disease (ADPKD).

KW - Cell proliferation

KW - Renal cancer

KW - V2-R antagonist

KW - V2-receptor

KW - Vasopressin

UR - http://www.scopus.com/inward/record.url?scp=78149408240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149408240&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2008.12.014

DO - 10.1016/j.urolonc.2008.12.014

M3 - Article

C2 - 19217806

AN - SCOPUS:78149408240

VL - 28

SP - 642

EP - 647

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 6

ER -